
The latest thought leadership from our expert teams

Let’s go! The new Catapult consortium is a brilliant boost for cell and gene therapy manufacturing
We’re thrilled to be a part of the CGT Catapult, working with 20 brilliant companies to accelerate the technology development for cell and gene therapy manufacturing.
- Bioinnovation

Rethinking Materials – it’s time to deliver some wins in packaging sustainability
With the world becoming increasingly impatient for a great sustainability reset, last week’s inaugural Rethinking Materials Virtual Summit did a pretty decent job at starting to shape the agenda for innovation in plastics and packaging over the next five or so years.
- Bioinnovation

Beyond AlphaFold: achieving new levels of protein performance through direct function prediction
Watch our webinar to discover how deep learning is allowing us to design optimized protein sequences to perform beyond those found in nature.
- AI & Analytics
- Bioinnovation
- Strategic advice

The challenge of scale down models
Scale-down models have become a popular development tool, especially in the bioprocessing industry. But how do you make them robust and reproducible?
- Bioinnovation

CellPreserve: our innovation could help prolong the lives of cancer patients
Diagnosing cancer early to treat it more effectively is vital. Here, Josh Gibson, senior physicist at Cambridge Consultants, unveils a potentially life-saving breakthrough in the field of liquid biopsy that’s been hailed by a leading innovation award jury…
- Bioinnovation
- Digital health

Tri-Con 2021 reflects the rapid pace of development in diagnostics
The past year has seen an unprecedented acceleration of innovation in the diagnostics space. Reflecting on the virtual themes and debates at Molecular Med Tri-Con 2021, Head of Life Sciences Symon Cotton says that the speed of tests and vaccines coming to market is not having an adverse effect on quality. Medical developments can be safely delivered to quicker timescales...
- Bioinnovation
- Digital health
- Human factors

What’s next for targeted medicine? We report back from SLAS 2021
Symon Cotton, Head of Life Sciences at Cambridge Consultants, attended this year’s Society for Laboratory Automation and Screening conference, SLAS2021. Even in virtual form, the speakers dazzled with fresh and exciting ideas for the future of patient treatments.
- Bioinnovation
- Digital health

Our core technology is at the heart of the world’s first FDA-approved fully at-home COVID-19 test
The rapid, at home COVID-19 antigen test from digital diagnostics company Ellume features core technology from Cambridge Consultants. Read how this FDA approved test is set to be a game-changer in the global pandemic.
- Bioinnovation
- Digital health
- Fluids & thermodynamics
- Sensing

UK Human Tissue Authority licence enhances our next-generation therapy development
We are delighted to report a significant step forward as we grow our bioinnovation capability as we have received our licence from the UK Human Tissue Authority to store human tissue for research purposes. This opens the way to future development in cell therapies and regenerative medicine.
- Bioinnovation

Mixing it up – a possible way to provide COVID-19 testing for all
Symon Cotton explores the use of pooled testing techniques for deploying mass Covid testing.
- Bioinnovation

Food, sustainability and COVID drive a sense of urgency at SynBioBeta 2020
James Hallinan's takeaway from SynBioBeta 2020: Synbio is growing up and getting ever more relevant to the everyday.
- Bioinnovation

Engineering the future of innovations in oncology
This paper highlights macro and micro factors affecting oncology and proposes a partnership-driven framework to catalyze innovation for oncology-focused biopharma – as well as the role that select high-impact technologies will have on the on the entire value-chain of cancer research and care delivery.
- AI & Analytics
- Bioinnovation
- Digital health
- Dispense
- Robotics
- Sensing